MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Parkinson’s"

  • 2023 International Congress

    Palliative Care in Parkinson: a family caregiver’s view. A PD-PAL Consortium initiative.

    D. Trivedi, M. Qamar, V. Leta, M. Meinders, C. Münte, M. Groot, A. Antonini, M. Garon, K. Ray Chaudhuri (London, United Kingdom)

    Objective: We aim to identify clinical indicators and markers for timely referral, access, and need of PC in our PwP community, from the viewpoint of…
  • 2023 International Congress

    The study of genetic factors in levodopa-induced motor complications development in Russian patients with Parkinson’s disease

    G. Akhmadeeva, I. Khidiyatova, I. Gilyazova, S. Umutbaev, R. Galimova, A. Baitimerov, R. Magzhanov (Ufa, Russian Federation)

    Objective: This study is aimed to explore the relationship between the single nucleotide polymorphisms (SNPs) in dopamine and serotonin metabolism genes, other neurotransmitter systems genes…
  • 2023 International Congress

    Correlation between dose of dopamine replacement therapy and King’s Parkinson’s Disease Pain Scale in Mexican Patients with Parkinson’s Disease

    A. Regalado Mustafá, D. Aguila Godinez, A. Herrera Ruiz, E. Santiago-de-La-Cruz, L. Lira Juárez, M. Medrano Delgado, M. Ruiz Mafud, A. Hernández-Medrano, D. Romero-Terán, M. Medina-Pérez, G. Cerda Hernández, M. Rodríguez-Violante, A. Cervantes-Arriaga, G. Hernandez Armesto, A. Abundes-Corona, A. Domínguez García, J. García Hernández, A. Alcocer Salas, K. Talavera Lagunas (Mexico City, Mexico)

    Objective: Investigate the relationship between the dose of dopamine replacement therapy (DRT) and pain severity as measured by the King's Parkinson's Disease Pain Scale (KPPS)…
  • 2023 International Congress

    Experience of the LARGE-PD protocol in a health center in Buenos Aires, Argentina

    N. Gonzalez Rojas, E. Gatto, I. Mata, C. Perandones, M. Inca, M. Cesarini, G. da Prat, J. Etcheverry (Buenos Aires, Argentina)

    Objective: Disseminate and inform the activity of the Latin American Research Consortium on the Genetics of Parkinson's Disease (LARGE-PD) in Argentina. Background: The LARGE-PD consortium…
  • 2023 International Congress

    The epigenetic association of Parkinson’s disease risk gene- GPNMB rs199347 with drinking

    YC. Chen, SL. Wu, YP. Liaw (Changhua, Taiwan)

    Objective: This paper examines the epigenetic association of rs199347 polymorphism variants of the GPNMB with drinking and DNA methylation changes. Background: Neuroinflammatory response induced by alcohol…
  • 2023 International Congress

    Does hyposmia induce apathy in early Parkinson’s disease? Lessons from structural brain connectivity

    A. Martinez-Nunez, H. Soltanian-Zadeh, K. Latack, N. Ghazi, A. Mahajan (Detroit, USA)

    Objective: To study changes in microstructural integrity of white matter tracts associated with apathy in patients with early Parkinson’s disease (PD) and hyposmia Background: Smells…
  • 2023 International Congress

    LRRK2 kinase activity regulates sphingolipid hydrolase enzymatic activities in different cell lines: induced pluripotent stem cell-derived dopaminergic neurons, primary monocyte‐derived macrophages and SH-SY5Y

    T. Usenko, K. Basharova, A. Bezrukova, A. Izyumchenko, M. Nikolaev, G. Baydakova, S. Pavlova, E. Grigorieva, S. Medvedev, E. Zakharova, S. Zakian, S. Pchelina (Gatchina, Russian Federation)

    Objective: To assess whether inhibition of the kinase activity of LRRK2 affects changes in enzyme activity of sphingolipid hydrolase in the culture of dopaminergic neurons…
  • 2023 International Congress

    Use of concomitant medications before and after treatment with levodopa/carbidopa intestinal gel in patients with advanced Parkinson’s disease: summary of phase 3 and real-world studies

    J. Boyd, H. Fernandez, W. Poewe, A. Fasano, N. Kovács, K. Chaudhuri, M. Simu, J. Aldred, L. Lopiano, S. Parashos, J. Parra, L. Bergmann, P. Kukreja, M. Shah, O. Ladhani, G. Melzi, C. Yan, A. Antonini (Burlington, USA)

    Objective: Evaluate the use of concomitant Parkinson’s disease (PD) medications before and after treatment with levodopa/carbidopa intestinal gel (LCIG) using data from phase 3 clinical…
  • 2023 International Congress

    Hypoxia‑induced astrocyte activation and its protective effect on Parkinson’s disease

    M. Kim, S-H. Kim, HN. Choi, JY. Je, SP. Yun (Jinju, Republic of Korea)

    Objective: In this study, we aimed to investigate whether hypoxic conditions can activate cerebral astrocytes and explore their protective effects on α-synuclein pre-formed fibril (PFF)-treated…
  • 2023 International Congress

    Improving inpatient medication management in hospitalized Parkinson’s patients

    R. Schell, J. Stroh, F. Phibbs, A. Depp, C. Eastburn, A. Boudreaux (Not Hispanic/Latino/Latina/Latinx, USA)

    Objective: Develop a process for Parkinson's patients to provide individualized medication management to reduce length of stay,, mortality, 30-day readmissions, and increase patient satisfaction. Background:…
  • « Previous Page
  • 1
  • …
  • 117
  • 118
  • 119
  • 120
  • 121
  • …
  • 338
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
      • Welcome to the MDS Abstracts Site
      • Effect of marijuana on Essential Tremor: A case report
      • Advanced Search
      • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
      • Covid vaccine induced parkinsonism and cognitive dysfunction
      • Help & Support
      • About Us
      • Cookies & Privacy
      • Wiley Job Network
      • Terms & Conditions
      • Advertisers & Agents
      Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
      Wiley